ITC Launches Investigation Into Imports of CNP-Based Drug Products Allegedly Infringing BioMarin Patent
May 08, 2025
May 08, 2025
WASHINGTON, May 8 (TNSFR) -- The U.S. International Trade Commission has instituted Investigation No. 337-TA-1447 following a complaint filed by BioMarin Pharmaceutical Inc., headquartered in Novato, California, alleging patent infringement involving certain drug products containing C-type natriuretic peptide (CNP) variants.
The complaint, received on April 2, 2025, under section 337 of the Tariff Act of 1930, accuses several foreign and domestic companies of unlawfully importing, . . .
The complaint, received on April 2, 2025, under section 337 of the Tariff Act of 1930, accuses several foreign and domestic companies of unlawfully importing, . . .